A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

Abstract
Because of the immunosuppression required, heart-transplant recipients frequently have complications caused by cytomegalovirus (CMV), including pneumonia, esophagitis, gastritis, and a syndrome of fever, hepatitis, and leukopenia. We undertook a controlled trial to evaluate the prophylactic administration of ganciclovir to prevent CMV-induced disease after heart transplantation.

This publication has 16 references indexed in Scilit: